Articles related to Ophthalmology

In a follow-up to a previous article on HCN, the Centers for Disease Control and Prevention (CDC) have recently updated their website to report that 68 patients across 16 states have been identified with a rare and drug-resistant strain of Pseudomonas aeruginosa called VIM-GES-CRPA (Verona integron-mediated metallo-β-lactamase). This strain is particularly concerning as it is difficult to treat with standard antibiotics. As a precaution, the CDC and FDA are recommending that clinicians and patients avoid using EzriCare or Delsam Pharma’s Artificial Tears products until further guidance is issued. Optometrists are advised to stay informed about the situation and to follow the CDC and FDA’s recommendations to ensure the safety of their patients.

This piece discusses the latest developments in myopia control and management. It highlights the importance of implementing myopia control strategies early on, as myopia is becoming more prevalent and severe in younger populations. The article discusses the different methods available for myopia control, such as orthokeratology, atropine therapy, and multifocal contact lenses. It also provides insight into emerging treatments, such as corneal reshaping with photorefractive intrastromal cross-linking (PiXL) and soft contact lenses with light-adjustable properties. The author emphasizes the importance of staying up-to-date with the latest research and technology to provide the best care for patients with myopia.

The every-other-month intra-ocular injection shows a reduction in lesion growth that increases over time. The ocular formulation of the drug, previously approved for paroxysmal nocturnal hemoglobinuria, should be available in specialty pharmacies in March 2023.

Dr. Seol Seung-Kwon of Korea Electrotechnology Research Institute (KERI) said, “Our achievement is a development of 3D printing technology that can print functional micro-patterns on non-planner substrate that can commercialize advanced smart contact lenses to implement AR.” He added, “It will greatly contribute to the miniaturization and versatility of AR devices.”

The current study is the largest case series (49 patients [50 eyes]) of retinal toxicity caused by a specific compounded formulation of triamcinolone-moxifloxacin to date. Patients were referred to Texas Retina Associates in Dallas after cataract surgery and were identified through an EMR system query up to 24 months after their initial presentation. This article describes the clinical presentation, course, and outcomes of a toxic posterior segment syndrome (TPSS) outbreak.

AvaGenTM is the first personalized genetic eye test that quantifies the risk of keratoconus and the presence of TGFBI corneal dystrophies based on gene variants. AvaGen provides a valuable tool for early and accurate decision-making that protects patients’ and their families’ vision.